Related references
Note: Only part of the references are listed.Enhanced phosphate absorption in intestinal epithelial cell-specific NHE3 knockout mice
Jianxiang Xue et al.
ACTA PHYSIOLOGICA (2022)
Effect of diuretics on plasma aldosterone and potassium in primary hypertension: A systematic review and meta-analysis
Ryan J. McNally et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R. Tuttle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
Are SGLT2 Inhibitors New Hypertension Drugs?
Kazuomi Kario et al.
CIRCULATION (2021)
Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats
Denisha R. Spires et al.
PHYSIOLOGICAL GENOMICS (2021)
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease
Mette Ostergaard et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)
Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats
Scott Culver Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
M. Arow et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease
Ningning Wan et al.
HYPERTENSION RESEARCH (2020)
Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model
Sohair Saleh et al.
JOURNAL OF GENETICS (2020)
Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences
Jessica A. Dominguez Rieg et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2020)
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Rachel J. Perry et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
Janani Rangaswami et al.
CIRCULATION (2020)
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta et al.
PHARMACOLOGICAL RESEARCH (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Role of opioid signaling in kidney damage during the development of salt-induced hypertension
Daria Golosova et al.
LIFE SCIENCE ALLIANCE (2020)
A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
Akira Onishi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)
SGLT-2 inhibitors in diabetes: a focus on renoprotection
Diego Ennes Gonzalez et al.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2020)
Differences in renal BMAL1 contribution to Na+ homeostasis and blood pressure control in male and female mice
G. Ryan Crislip et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)
SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients
Evan C. Ray et al.
KIDNEY MEDICINE (2020)
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Tune 2 Diabetes
Jin Bong Choi et al.
INTERNATIONAL NEUROUROLOGY JOURNAL (2020)
Phosphate, the forgotten mineral in hypertension
Han-Kyul Kim et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2019)
Animal Models of Hypertension: A Scientific Statement From the American Heart Association
Lilach O. Lerman et al.
HYPERTENSION (2019)
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Tuba M. Ansary et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
Sungjin Chung et al.
FRONTIERS IN PHYSIOLOGY (2019)
Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet
Tomonari Kimura et al.
INTERNATIONAL HEART JOURNAL (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Andre J. Scheen
CURRENT CARDIOLOGY REPORTS (2019)
Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study
Kazuomi Kario et al.
CIRCULATION (2019)
Relationship between the renin-angiotensin-aldosterone system and renal Kir5.1 channel
Anna D. Manis et al.
CLINICAL SCIENCE (2019)
Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice
Chao Ma et al.
NEPHRON (2019)
Direct and indirect inhibition of the circadian clock protein Per 1: effects on ENaC and blood pressure
Abdel Alli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Progression of diabetic kidney disease in T2DN rats
Oleg Palygin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Vibrodissociation method for isolation of defined nephron segments from human and rodent kidneys
Elena Isaeva et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Postprandial Effects on ENaC-Mediated Sodium Absorption
Gregory Blass et al.
SCIENTIFIC REPORTS (2019)
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
T. Cooper Woods et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats
Lei Li et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2018)
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
Ali F. Abdel-Wahab et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
Ichiro Mori et al.
DIABETES (2018)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg et al.
DIABETOLOGIA (2018)
Characterization of purinergic receptor expression in ARPKD cystic epithelia
Oleg Palygin et al.
PURINERGIC SIGNALLING (2018)
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Paola Cassis et al.
JCI INSIGHT (2018)
Renal Na-handling defect associated with PER1-dependent nondipping hypertension in male mice
Lauren G. Douma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Hypertension and Diabetes Mellitus The Chicken and Egg Problem
Alexander Staruschenko
HYPERTENSION (2017)
High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5
Juan Wang et al.
PLOS ONE (2017)
Lack of Effects of Metformin and AICAR Chronic Infusion on the Development of Hypertension in Dahl Salt-Sensitive Rats
Tengis S. Pavlov et al.
FRONTIERS IN PHYSIOLOGY (2017)
Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats
Tuba M. Ansary et al.
SCIENTIFIC REPORTS (2017)
Essential role of Kir5.1 channels in renal salt handling and blood pressure control
Oleg Palygin et al.
JCI INSIGHT (2017)
Salt and hypertension in diabetes
Takashi Uzu
DIABETOLOGY INTERNATIONAL (2017)
Evidence of the Importance of Nox4 in Production of Hypertension in Dahl Salt-Sensitive Rats
Allen W. Cowley et al.
HYPERTENSION (2016)
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Ling Chen et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
T. D. Filippatos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
Yui Takeshige et al.
HYPERTENSION RESEARCH (2016)
Renal sodium transport in renin-deficient Dahl salt-sensitive rats
Tengis S. Pavlov et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2016)
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
Seok Joon Shin et al.
PLOS ONE (2016)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
The Circadian Clock in the Regulation of Renal Rhythms
Kristen Solocinski et al.
JOURNAL OF BIOLOGICAL RHYTHMS (2015)
Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
Daniel Rodriguez et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2015)
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats
Lodi C. W. Roksnoer et al.
KIDNEY INTERNATIONAL (2015)
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
Naoki Kojima et al.
PHYSIOLOGICAL REPORTS (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Deficiency of Renal Cortical EGF Increases ENaC Activity and Contributes to Salt-Sensitive Hypertension
Tengis S. Pavlov et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?
Usha Panchapakesan et al.
PLOS ONE (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Large-scale phosphoproteomic analysis of membrane proteins in renal proximal and distal tubule
Marina Feric et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Chromosome substitution reveals the genetic basis of Dahl salt-sensitive hypertension and renal disease
David L. Mattson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet
H Kobori et al.
HYPERTENSION (2003)
Share Paper
